DocGo vs GeneDx
DCGO and WGS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DCGO and WGS compare
GeneDx is the larger company, worth 84 times as much as DocGo ($1.5B against $18.1M).
GeneDx grew revenue faster over the last twelve months (25.4% versus −32.4% for DocGo).
GeneDx keeps more of each dollar of sales as profit, with a net margin of −23.4% compared with −65.3% at DocGo.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DCGO | WGS |
|---|---|---|
| Size and price | ||
| Market cap | $18.1M | $1.5B |
| Share price | $0.183 | $51.02 |
| Change, 1 year | −82.9% | −60.9% |
| Change, 5 years | −97.6% | −77.6% |
| Beta (5Y) | 2.22 | 0.82 |
| Employees | 3,600 | 1,300 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.1× (better) | 3.3× |
| P/B | 0.2× (better) | 6.2× |
| FCF yield | −143% | −5.0% (better) |
| Fair value | $3.10 | $32.23 |
| Margin of safety | 94.1% (better) | −58.3% |
| Growth | ||
| Revenue growth (TTM) | −32.4% | 25.4% (better) |
| Revenue growth, 5Y average | 27.9% (better) | 19.0% |
| Net income growth (TTM) | – | −7665% |
| EPS growth (TTM) | – | −18300% |
| Profitability | ||
| Gross margin | – | 69.4% |
| Operating margin | −62.2% | −20.3% (better) |
| Net margin | −65.3% | −23.4% (better) |
| FCF margin | −8.8% (better) | −16.7% |
| Return on equity | −92.4% | −40.8% (better) |
| Return on invested capital | −101% | −36.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.40 |
| Current ratio | 1.66 | 3.30 (better) |
| Altman Z-score | −2.84 | 0.36 (better) |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 38.5% | 107% |
| Held by insiders | 9.8% | – |
| Insider net buying, 12 months | −$15.3K | $91.2M (better) |
| Short interest, % of float | 2.4% | – |
Go deeper
- DCGO stock overview
- DCGO income statement
- DCGO valuation and score
- WGS stock overview
- WGS income statement
- WGS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.